Contrasting ABIOMED (ABMD) & The Competition
ABIOMED (NASDAQ: ABMD) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare ABIOMED to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
This table compares ABIOMED and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for ABIOMED and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ABIOMED currently has a consensus price target of $167.57, suggesting a potential downside of 2.46%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 20.87%. Given ABIOMED’s stronger consensus rating and higher possible upside, equities analysts plainly believe ABIOMED is more favorable than its rivals.
Volatility and Risk
ABIOMED has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, ABIOMED’s rivals have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
Insider and Institutional Ownership
89.7% of ABIOMED shares are held by institutional investors. Comparatively, 53.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 7.0% of ABIOMED shares are held by company insiders. Comparatively, 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares ABIOMED and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ABIOMED||$474.78 million||$110.92 million||101.66|
|ABIOMED Competitors||$2.02 billion||$430.74 million||-69.45|
ABIOMED’s rivals have higher revenue and earnings than ABIOMED. ABIOMED is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
ABIOMED beats its rivals on 8 of the 13 factors compared.
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.